Study of AIGIV safety and benefits in systemic anthrax
Part of Infections clinical trials.
This is an observational study (doctors follow people and record outcomes) for patients with systemic anthrax who received AIGIV from the CDC. It aims to learn how safe AIGIV is and what clinical outcomes patients experience after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed or suspected systemic anthrax (a serious whole-body form).
- You are being cared for in the USA (or another location if possible).
- You were treated with AIGIV (ANTHRASIL®) provided by the CDC.
- Your case fits one of the listed anthrax evidence types (exposure link, lab tests, or antibody/DNA/antigen test results).
- You can give informed consent (or a child can assent with consent as applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who received the CYFENDUS vaccine to prevent anthrax after a large-scale exposure event. It will check how well the vaccine works and if there are any safety concerns.
This trial studies how safe and potentially helpful ANTHRASIL (AIGIV) is for people who have inhalational anthrax after exposure to a known source. If you have suspected or confirmed inhalational anthrax and were treated with AIGIV, you may be able to join this safety-and-benefit study.
This study observes people in the U.S. who have been treated with a specific anthrax drug (raxibacumab) from the national emergency supply. It helps doctors learn more about how the drug works in real-world cases of anthrax infection.
This study looks at how safe and helpful raxibacumab is for people who are sick with inhalational anthrax after being exposed in a large incident. It includes all ages and also includes pregnant and breastfeeding people, focusing on outcomes from standard emergency clinical care.
This study tests a new vaccine called VAX-A1 in healthy people aged 18–40 to see if it's safe and if it helps the body build protection against Group A Streptococcus (a bacteria that can cause serious infections). You'll receive two vaccine doses and have blood tests and heart monitoring over 6 months.
This trial looks at how well a medicine called VIGIV works for people who develop serious or unusual vaccinia (smallpox-type) infections or complications after smallpox vaccination. It is mainly for specific skin and body-area problems, including eczema-related complications.
Hear when a new Anthrax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.